载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究

doi:10.3969/j.issn.1673-5765.2026.05.008

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (5): 577-584.DOI: 10.3969/j.issn.1673-5765.2026.05.008

载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究

李汶逸¹，姜季委²，任琦玮¹，王琳琳¹，赵敏¹，徐俊¹

1北京 100070 首都医科大学附属北京天坛医院神经病学中心，神经系统疾病国家临床医学研究中心
2北京 100070 首都医科大学附属北京天坛医院健康管理中心

收稿日期:2025-09-01 修回日期:2026-05-12 接受日期:2026-05-20 出版日期:2026-05-20 发布日期:2026-05-20
通讯作者: 徐俊 neurojun@126.com
基金资助:
四大慢病重大专项（2023ZD0505804）
国家重点研发计划（2024YFF0507503）
国家自然科学基金（82471212）

A Study on the Correlation between Apolipoprotein E Gene Polymorphism and Cognitive Function Changes after Stroke

LI Wenyi¹, JIANG Jiwei², REN Qiwei¹, WANG Linlin¹, ZHAO Min¹, XU Jun¹#br#

1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing 100070, China
2Health Management Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received:2025-09-01 Revised:2026-05-12 Accepted:2026-05-20 Online:2026-05-20 Published:2026-05-20
Contact: XU Jun, E-mail: neurojun@126.com

摘要/Abstract

摘要： 目的分析不同载脂蛋白E（apolipoprotein E，APOE）基因型急性缺血性卒中患者的临床特征差异，探讨APOE基因多态性与卒中后认知功能变化的相关性。
方法本研究基于多中心、前瞻性的中国血管性认知障碍预测、预防和个性化研究，纳入2022年9月1日—2023年8月31日中国6家医疗机构收治的急性缺血性卒中患者，收集入组患者基线期年龄、性别、受教育年限、BMI、既往史（高血压、糖尿病、心脏病、高脂血症、卒中或TIA）、吸烟史、饮酒史、药物治疗史、NIHSS评分、MoCA评分、汉密尔顿抑郁量表（Hamilton depression scale，HAMD）评分、汉密尔顿焦虑量表（Hamilton anxiety scale，HAMA）评分、影像学资料（是否关键部位梗死、梗死体积分级）、TOAST分型，以及APOE基因型。根据APOE基因型，将患者分为APOE ε3纯合子（ε3/ε3）、APOE ε2携带者（ε2/ε3、ε2/ε2）和APOE ε4携带者（ε3/ε4、ε4/ε4）3组，并在发病后6～12个月对患者进行随访。对3组患者上述基线期临床资料进行单因素方差分析，采用广义线性混合模型分析APOE基因型与卒中后MoCA评分纵向变化的相关性。
结果本研究在基线期共纳入急性缺血性卒中患者202例，其中男性155例、女性47例，年龄（58.5±10.4）岁。3组不同APOE基因型患者的基线期年龄、性别、受教育年限、BMI、既往史、吸烟史、饮酒史、药物治疗史、NIHSS评分、MoCA评分、HAMD评分、HAMA评分、关键部位梗死比例、梗死体积分级及TOAST分型的组间差异均无统计学意义（均P>0.05）。共151例患者完成随访，中位随访时间为8.0（7.0～10.0）个月。校正性别、年龄、受教育年限和中心效应后发现，与APOE ε3纯合子相比，APOE ε4携带者与基线期MoCA评分呈负相关（β=-1.682，P=0.029），随访时间和APOE ε4携带者的交互作用与MoCA评分呈负相关（β=-0.322，P<0.001）。
结论 APOE基因多态性与卒中后认知功能评分的变化有关，与APOE ε3纯合子相比，APOE ε4携带者在卒中时认知功能评分更低，且卒中后认知功能评分下降速度更快。

文章导读： 本研究基于我国多中心前瞻性急性缺血性卒中患者队列，动态分析了不同载脂蛋白E基因型患者卒中后认知轨迹的差异，发现载脂蛋白E ε4携带者认知功能下降速度更快，为卒中后认知障碍高危人群的早期识别和个体化干预提供了客观、可靠的本土化遗传学依据。

关键词: 急性缺血性卒中; 认知功能; 载脂蛋白E; 基因多态性

Abstract: Objective To investigate the differences in clinical characteristics among various apolipoprotein E (APOE) genotypes in patients with acute ischemic stroke, and to explore the association between APOE gene polymorphism and changes in cognitive function after stroke.
Methods This study was based on a multicenter, prospective study (predictive, preventive and personalized project of vascular cognitive impairment in China). Patients with acute ischemic stroke admitted to six medical institutions in China from September 1, 2022 to August 31, 2023 were enrolled. Baseline data collected at enrollment included age, sex, years of education, BMI, medical history (hypertension, diabetes mellitus, heart disease, hyperlipidemia, stroke or TIA), smoking history, drinking history, medication history, NIHSS score, MoCA score, Hamilton depression scale (HAMD) score, Hamilton anxiety scale (HAMA) score, imaging data (whether critical site infarction, infarct size grade), TOAST classification, and APOE genotype. Patients were categorized into three groups based on their APOE genotypes: APOE ε3 homozygotes (ε3/ε3), APOE ε2 carriers (ε2/ε3, ε2/ε2), and APOE ε4 carriers (ε3/ε4, ε4/ε4). The patients were followed up 6 to 12 months after stroke onset. One-factor analysis of variance was performed to compare the above baseline clinical data among the three groups. Additionally, generalized linear mixed models were utilized to analyze the correlation between APOE genotypes and the longitudinal changes in MoCA scores after stroke.
Results A total of 202 patients with acute ischemic stroke were included at baseline, including 155 males and 47 females, with a mean age of (58.5±10.4) years. There were no statistically significant differences in baseline age, sex, years of education, BMI, medical history, smoking history, drinking history, medication history, NIHSS score, MoCA score, HAMD score, HAMA score, proportion of critical site infarction, infarct size grade, or TOAST classification among the three groups of patients with different APOE genotypes (all P>0.05). A total of 151 patients completed the follow-up, and the median follow-up period was 8.0 (7.0-10.0) months. After adjusting for sex, age, years of education, and center effect, it was found that compared with the APOE ε3 homozygotes, the APOE ε4 carriers showed a significant negative correlation with MoCA score at baseline (β=-1.682, P=0.029), and the interaction between follow-up period and APOE ε4 carrier status was also significantly negatively correlated with MoCA score (β=-0.322, P<0.001).
Conclusions The polymorphism of the APOE gene is related to the changes in cognitive function scores after stroke. Compared with the APOE ε3 homozygotes, APOE ε4 carriers exhibit lower cognitive function scores at stroke onset, and show a more rapid decline in cognitive function scores after stroke.

Key words: Acute ischemic stroke; Cognitive function; Apolipoprotein E; Gene polymorphism

中图分类号:

李汶逸, 姜季委, 任琦玮, 王琳琳, 赵敏, 徐俊. 载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究[J]. 中国卒中杂志, 2026, 21(5): 577-584.

LI Wenyi, JIANG Jiwei, REN Qiwei, WANG Linlin, ZHAO Min, XU Jun. A Study on the Correlation between Apolipoprotein E Gene Polymorphism and Cognitive Function Changes after Stroke[J]. Chinese Journal of Stroke, 2026, 21(5): 577-584.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.chinastroke.org.cn/CN/10.3969/j.issn.1673-5765.2026.05.008

https://www.chinastroke.org.cn/CN/Y2026/V21/I5/577

参考文献

[1] 中国卒中学会血管性认知障碍分会. 中国血管性认知障碍诊治指南（2024版）[J]. 中华医学杂志，2024，104（31）：2881-2894.
Chinese Stroke Association Vascular Cognitive Impairment Subcommittee. Chinese guidelines for the diagnosis and treatment of vascular cognitive impairment（2024 edition）[J]. Natl Med J China，2024，104（31）：2881-2894.
[2] EL HUSSEINI N，KATZAN I L，ROST N S，et al. Cognitive impairment after ischemic and hemorrhagic stroke：a scientific statement from the American Heart Association/American Stroke Association[J/OL]. Stroke，2023，54（6）：e272-e291[2026-04-30]. https://doi.org/10.1161/STR.0000000000000430.
[3] GALLUCCI L，SPERBER C，GUGGISBERG A G，et al. Post-stroke cognitive impairment remains highly prevalent and disabling despite state-of-the-art stroke treatment[J]. Int J Stroke，2024，19（8）：888-897.
[4] KRISHNAMURTHY H K，JAYARAMAN V，KRISHNA K，et al. An overview of the genes and biomarkers in Alzheimer’s disease[J/OL]. Ageing Res Rev，2025，104：102599[2026-04-30]. https://doi.org/10.1016/j.arr.2024.102599.
[5] CHEN J H，CHAN L，HONG C T，et al. Role of apolipoprotein E（ApoE）ε4 in cognitive impairment after a stroke：a prospective cohort study[J]. Aging（Albany NY），2025，17（5）：1261-1274.
[6] WERDEN E，KHLIF M S，BIRD L J，et al. APOE ɛ4 carriers show delayed recovery of verbal memory and smaller entorhinal volume in the first year after ischemic stroke[J]. J Alzheimers Dis，2019，71（1）：245-259.
[7] DEC-ĆWIEK M，WRONA P，HOMA T，et al. Incidence and factors associated with cognitive impairment 90 days after first ever ischemic stroke[J/OL]. Int J Geriatr Psychiatry，2025，40（5）：e70087[2026-04-30]. https://doi.org/10.1002/gps.70087.
[8] WANG L L，JIANG J W，WANG Y L，et al. Predictive，preventive and personalized project of vascular cognitive impairment in China（P3）：study design and interim baseline patient characteristics of a nationwide multicenter prospective registry[J]. Aging Med（Milton），2024，7（6）：744-753.
[9] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志，2024，57（6）：523-559.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chin J Neurol，2024，57（6）：523-559.
[10] DUERING M，BIESSELS G J，BRODTMANN A，et al. Neuroimaging standards for research into small vessel disease-advances since 2013[J]. Lancet Neurol，2023，22（7）：602-618.
[11] ADAMS H P，Jr，BENDIXEN B H，KAPPELLE L J，et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment[J]. Stroke，1993，24（1）：35-41.
[12] WEAVER N A，KUIJF H J，ABEN H P，et al. Strategic infarct locations for post-stroke cognitive impairment：a pooled analysis of individual patient data from 12 acute ischemic stroke cohorts[J]. Lancet Neurol，2021，20（6）：448-459.
[13] KATAN M，FLURI F，MORGENTHALER N G，et al. Copeptin：a novel，independent prognostic marker in patients with ischemic stroke[J]. Ann Neurol，2009，66（6）：799-808.
[14] REN L B，HU F，WALSH S，et al. Healthy lifestyle factors outweigh influence of APOE genetic risk on extending cognitively healthy life expectancy among Chinese older adults：evidence from a nationwide cohort study[J/OL]. Alzheimers Dement，2025，21（4）：e70090[2026-04-30]. https://doi.org/10.1002/alz.70090.
[15] PETTIGREW C，NAZAROVS J，SOLDAN A，et al. Alzheimer’s disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals[J/OL]. Alzheimers Res Ther，2023，15（1）：66[2026-04-30]. https://doi.org/10.1186/s13195-023-01206-9.
[16] LEVINE D A，CHEN B X，GALECKI A T，et al. Associations between vascular risk factor levels and cognitive decline among stroke survivors[J/OL]. JAMA Netw Open，2023，6（5）：e2313879[2026-04-30]. https://doi.org/10.1001/jamanetworkopen.2023.13879.
[17] MA C H，WANG D J，HONG Z K，et al. Relationship between genetic polymorphism and cognitive impairment in patients with acute ischemic stroke（APOE）[J]. Altern Ther Health Med，2024，30（11）：92-97.
[18] SALAH KHLIF M，EGOROVA-BRUMLEY N，BIRD L J，et al. Cortical thinning 3 years after ischaemic stroke is associated with cognitive impairment and APOE ε4[J/OL]. Neuroimage Clin，2022，36：103200[2026-04-30]. https://doi.org/10.1016/j.nicl.2022.103200.
[19] PENDLEBURY S T，POOLE D，BURGESS A，et al. APOE-ε4 genotype and dementia before and after transient ischemic attack and stroke：population-based cohort study[J]. Stroke，2020，51（3）：751-758.
[20] AKINYEMI R O，ALLAN L M，OAKLEY A，et al. Hippocampal neurodegenerative pathology in post-stroke dementia compared to other dementias and aging controls[J/OL]. Front Neurosci，2017，11：717[2026-04-30]. https://doi.org/10.3389/fnins.2017.00717.
[21] FILLER J，GEORGAKIS M K，DICHGANS M. Risk factors for cognitive impairment and dementia after stroke：a systematic review and meta-analysis[J/OL]. Lancet Healthy Longev，2024，5（1）：e31-e44[2026-04-30]. https://doi.org/10.1016/S2666-7568(23)00217-9.
[22] MCCULLOUGH L D. The murky waters of sex differences in post-stroke cognitive impairment[J]. Nat Rev Neurol，2023，19（11）：641-642.
[23] WANG Y，LIU H C，YE Y J，et al. ApoE2 affects insulin signaling in the hippocampus and spatial cognition of aged mice in a sex-dependent manner[J/OL]. Cell Commun Signal，2025，23（1）：112[2026-04-30]. https://doi.org/10.1186/s12964-025-02093-3.
[24] JACKSON R J，KEISER M S，MELTZER J C，et al. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease[J]. Mol Ther，2024，32（5）：1373-1386.

载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究

A Study on the Correlation between Apolipoprotein E Gene Polymorphism and Cognitive Function Changes after Stroke

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	何丹丹, 李俭, 王春娟, 李姝雅. 我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破[J]. 中国卒中杂志, 2026, 21(5): 517-524.
[2]	程希玥, 赵璟妍, 王春娟. 依达拉奉右莰醇在急性缺血性卒中脑细胞保护中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 526-532.
[3]	杨千千, 张眉扬, 陆瑶, 周东杨, 王正一蕾, 单舒乙, 刘晨辉, 王伊龙, 管玲. 米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据[J]. 中国卒中杂志, 2026, 21(5): 533-542.
[4]	何丹丹, 李姝雅. 基于STAIR原则的PSD-95靶向脑细胞保护剂在急性缺血性卒中中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 543-552.
[5]	常曹文静, 许淑红, 李俭, 李姝雅. 载脂蛋白E基因与缺血性卒中后脑损伤关系的研究进展[J]. 中国卒中杂志, 2026, 21(5): 570-576.
[6]	刘元昊, 吴磊, 杨欢, 朱佳颖, 李亚哲. 不同取栓装置在急性缺血性卒中治疗中的有效性与安全性：1项回顾性比较研究[J]. 中国卒中杂志, 2026, 21(4): 463-470.
[7]	欧茹, 刘益民, 徐智坚, 黄文纯. 血管源性腔隙灶对急性缺血性卒中患者生命健康状况的动态影响[J]. 中国卒中杂志, 2026, 21(3): 312-319.
[8]	李荔, 段振晖, 高爱华, 潘宋斌. 老年急性缺血性卒中患者衰弱指数、营养风险与静脉溶栓后院内感染风险的相关性分析及预测模型构建[J]. 中国卒中杂志, 2026, 21(3): 331-337.
[9]	张自立, 赵颖, 孟珩, 徐安定. 急性缺血性卒中血管内治疗后无效再通预测研究进展[J]. 中国卒中杂志, 2026, 21(3): 378-386.
[10]	姚莉, 吴川杰. 2026美国心脏学会/美国卒中学会急性缺血性卒中患者早期管理指南血管内治疗要点与解读[J]. 中国卒中杂志, 2026, 21(2): 234-239.
[11]	何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.
[12]	黄旭阳, 李润辉. 替奈普酶与阿替普酶治疗急性缺血性卒中短期神经功能恢复比较：线性混合效应模型分析[J]. 中国卒中杂志, 2026, 21(1): 31-37.
[13]	何丹丹, 冯宝玉, 刘改芬, 谷鸿秋, 李姝雅. 中性粒细胞与淋巴细胞比值对急性缺血性卒中静脉溶栓患者预后的预测价值：基于3项随机对照试验的个体患者数据分析[J]. 中国卒中杂志, 2026, 21(1): 38-47.
[14]	赵敏, 冯宝玉, 何丹丹, 王维聪, 李姝雅. 瑞替普酶与阿替普酶治疗急性缺血性卒中合并心律失常患者的有效性及安全性比较[J]. 中国卒中杂志, 2026, 21(1): 48-54.
[15]	何丹丹, 李姝雅. 急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展[J]. 中国卒中杂志, 2026, 21(1): 55-64.